<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Much of our understanding of the molecular anomalies involved in the process of <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> has resulted from research into malignant <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e>, facilitated by the accessibility of hematopoietic cells </plain></SENT>
<SENT sid="1" pm="."><plain>For example, in <z:mp ids='MP_0002022'>lymphoid tumors</z:mp>, rearrangement of the genomic DNA can lead to the juxtaposition of proto-oncogenes and the highly active sequences regulating synthesis of immunoglobulins or T-cell receptors </plain></SENT>
<SENT sid="2" pm="."><plain>The subsequent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> results from an uncontrolled overexpression of a <z:mpath ids='MPATH_458'>normal</z:mpath> protein </plain></SENT>
<SENT sid="3" pm="."><plain>This type of "quantitative" anomaly occurs in follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> where B-cells overexpress the <z:mpath ids='MPATH_458'>normal</z:mpath> BCL2 protein which inhibits <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, contributing to immortalization of the B done </plain></SENT>
<SENT sid="4" pm="."><plain>The same type of rearrangement process can approach gene fragments which fusion and lead to production of a highly oncogenic chimerical or truncated abnormal protein </plain></SENT>
<SENT sid="5" pm="."><plain>Such "qualitative" anomalies occur in myeloid hemopathies </plain></SENT>
<SENT sid="6" pm="."><plain>Both types of anomalies involve genes controlling the cell cycle, cell differentiation or cell <z:hpo ids='HP_0011420'>death</z:hpo> (<z:mpath ids='MPATH_3'>apoptosis</z:mpath>), in particular transcription factors (for example, E2A, RARA, MYC) and molecules involved in signal transduction (for example <z:mp ids='MP_0011356'>RAS</z:mp>, ABL, LCK) </plain></SENT>
<SENT sid="7" pm="."><plain>A molecular anomaly can be detected in approximately 30% of <z:hpo ids='HP_0000001'>all</z:hpo> cases of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> and in up to 75% of the non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Analysis of the junction fragments of the different heavy chains of the immunoglobulins produced in these cases provides a specific marker for detecting the B or T-cell clone in digestive or skin biopsies </plain></SENT>
<SENT sid="9" pm="."><plain>For example, detection of a BCR-ABL transcript in a patient with <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">primary thrombocythemia</z:e> or an atypical myeloproliferative syndrome can be diagnostic and detection of the donal immunoglobulin or T-cell receptor rearrangement can confirm the malignant nature of the lymphoid proliferation </plain></SENT>
<SENT sid="10" pm="."><plain>Molecular markers also have prognostic value allowing patient stratification and more adapted therapy </plain></SENT>
<SENT sid="11" pm="."><plain>Molecular anomalies detected in malignant <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> are thus examples of nearly perfect "<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific" markers </plain></SENT>
</text></document>